Page last updated: 2024-09-05

erlotinib hydrochloride and Lymphoma, B-Cell

erlotinib hydrochloride has been researched along with Lymphoma, B-Cell in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goldman, B1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Lymphoma, B-Cell

ArticleYear
For investigational targeted drugs, combination trials pose challenges.
    Journal of the National Cancer Institute, 2003, Dec-03, Volume: 95, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States

2003